

August 30, 2007



Pressure BioSciences, Inc. Issued First Patent in Canada

WEST BRIDGEWATER, Mass., Aug. 30 /PRNewswire-FirstCall/ -- Pressure BioSciences, Inc. (Nasdaq: PBIO) ("PBI") today announced that it has been issued its first patent by the Canadian Intellectual Property Office. Entitled "Pressure-Mediated Binding of Biomolecular Complexes" (Number 2,259,318), this issuance extends the coverage of the Company's pressure cycling technology (PCT) patents previously issued in the United States, Japan, Germany, Italy, France, Sweden, Switzerland, and the U.K. The PCT methods covered by this patent relate to the association and disassociation of biomolecular complexes (such as antigen/antibody complexes) and the separation of biomolecules (such as proteins) from complex mixtures. Such methods may better enable the separation and purification of biomolecules (procedures that are performed routinely in pharmaceutical, biotechnology, and research laboratories) and may also improve the speed and sensitivity of both research and diagnostic tests, such as those used worldwide in the cancer, endocrine, and infectious diseases areas.

Richard T. Schumacher, Founder, President, and CEO of PBI said: "We continue to focus our primary PCT efforts in the potentially large and rewarding area of sample preparation. We concomitantly look to add value by reviewing our extensive patent portfolio outside of sample preparation to determine if our PCT intellectual property may help others improve their efforts in the therapeutic, diagnostics, or research areas."

Schumacher continued: "The PCT methods covered by this patent have the potential to play a significant role in improving the speed, ease-of-use, and sensitivity of both diagnostic and research tests currently used in laboratories today. The addition of Canada to the list of countries in which patents with similar claims have already been issued adds measurably to the value of this exciting PCT application."

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (PBI) is a publicly traded, early-stage company focused on the development of a novel, enabling technology called Pressure Cycling Technology (PCT). PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels (up to 35,000 psi and greater) to control bio-molecular interactions. PBI currently holds 13 US and 6 foreign patents covering multiple applications of PCT in the life sciences field, including such areas as genomic and proteomic sample preparation, pathogen inactivation, the control of chemical reactions, immunodiagnostics, and protein purification.

Forward Looking Statements

Statements contained in this press release regarding the Company's intentions, hopes, beliefs, expectations or predictions of the future are "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements

relating to the potential of the Company's PCT in sample preparation and for other applications, the protection that issued patents may provide, and the size of the commercial markets for PCT applications. These statements are based upon the Company's current expectations, forecasts, and assumptions that are subject to risks, uncertainties, and other factors that could cause actual outcomes and results to differ materially from those indicated by these forward-looking statements. These risks, uncertainties, and other factors include, but are not limited to: the risk that the Company's products will not achieve market acceptance in the area of sample preparation or in other applications; the risk that the Company's issued patents, including the newly issued Canadian patent, may not prevent competitors from developing and selling competitive technology; the risk that, due to the technological developments of others, the Company may be unable to continue to extend its patent protection; and the other risks and uncertainties discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-KSB for the year ended December 31, 2006 and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

Visit us at our website <http://www.pressurebiosciences.com>

Investor Contacts:

Richard T. Schumacher, President & CEO
Edward H. Myles, Senior Vice President
of Finance & CFO

Pressure BioSciences, Inc.
(508) 580-1818 (T)

SOURCE Pressure BioSciences, Inc.